New York State Issues Permit to Asuragen to Offer Fragile X, Thyroid Cancer MDx | GenomeWeb

NEW YORK (GenomeWeb) – Asuragen today announced it has received a clinical laboratory permit from New York state to offer the company's Xpansion Interpreter and miRInform Thyroid tests in the state.

The Austin, Texas-based firm can now offer the tests in all 50 states in the US, it said.

Xpansion Interpreter is a reflex test for fragile X carriers. It determines the total number of CGG repeats and number of AGG interruptions in the Fragile X Mental Retardation gene and can help determine the risk for potential parents of having a child with fragile X syndrome.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The startup incubator Y Combinator is launching a nonprofit research lab.

In Nature this week: genomic analysis of 200 bird species, and more.

The Australian High Court rules that isolated genetic material cannot be patented.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.

Sponsored by

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Sponsored by

This webinar will focus on a range of research and clinical applications enabled by improvements in mate pair technology for whole genome sequencing. 

Sponsored by
Oracle Health Sciences

Brian Wells of Penn Medicine will detail how his team's "PennOmics" integrated healthcare data warehouse accelerates clinical trial recruitment at the point of care, accepts data from wearables, and does it all in a secure, HIPAA- and research-compliant fashion.